Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$12.51 USD

12.51
256,355

+0.29 (2.37%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Inogen (INGN) Beats Earnings and Revenue Estimates in Q1

Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.

    Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More

    Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.

      Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y

      Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.

        Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates

        Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.

          IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View

          IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.

            ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates

            ResMed Inc. (RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level.

              Abaxis (ABAX) Beats Q4 Earnings Estimates, Revenues In Line

              Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2017 adjusted earnings per share of 33 cents, a penny ahead of the Zacks Consensus Estimate.

                athenahealth (ATHN) Misses on Earnings & Revenues in Q1

                athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.

                  Mead Johnson (MJN) Lags Q1 Earnings, Awaits Merger Closure

                  Mead Johnson Nutrition Company (MJN) reported first-quarter 2017 adjusted earnings per share (EPS) of 80 cents at constant exchange rate or CER, down 8% year over year.

                    Zimmer Biomet (ZBH) Beats on Q1 Earnings, Lowers Guidance

                    Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2017 adjusted earnings per share (EPS) of $2.13, up 6% year over year.

                      Boston Scientific (BSX) Misses on Q1 Earnings, Updates View

                      Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.

                        Varian Medical (VAR) Beats on Earnings and Revenues in Q2

                        Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 89 cents per share in the second quarter of fiscal 2017, which beat the Zacks Consensus Estimate by a penny.

                          Pacific Biosciences (PACB) Q1 Loss Wider than Estimated

                          Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.

                            Integra LifeSciences (IART) Misses Q1 Earnings, Retains View

                            Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.

                              Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance

                              Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.

                                Illumina (ILMN) Posts In-line Earnings in Q1, Margins Down

                                Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 64 cents in the first quarter of 2017

                                  Edwards Lifesciences (EW) Tops Q1 Earnings, Updates '17 View

                                  Edwards Lifesciences Corp. (EW) reported first-quarter 2017 adjusted earnings per share (EPS) of 94 cents, which surpassed the Zacks Consensus Estimate by 14.6%.

                                    Baxter International (BAX) Q1 Earnings Beat, FY17 View Up

                                    Baxter International Inc. (BAX) reported first-quarter 2017 adjusted earnings of 58 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents and was way better than the year-ago figure of 36 cents.

                                      NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View

                                      NuVasive, Inc. (NUVA) reported first-quarter 2017 adjusted earnings per share (EPS) of 38 cents, reflecting an 18.7% rise from the year-ago quarter.

                                        LabCorp (LH) Tops Q1 Earnings, Misses on Sales, Tweaks View

                                        Laboratory Corporation of America Holdings (LH) or LabCorp reported first-quarter 2017 adjusted earnings per share (EPS) of $2.22, up 8.3% from the year-ago quarter.

                                          Express Scripts (ESRX) Earnings Top in Q1, FY17 View Up

                                          Express Scripts Holding Company (ESRX) posted first-quarter 2017 adjusted earnings per share of $1.33, beating the Zacks Consensus Estimate by a penny.

                                            C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up

                                            C.R. Bard Inc. (BCR) reported adjusted earnings of $2.87 in the first quarter of 2017, exceeding the Zacks Consensus Estimate of $2.65.

                                              Baxter Launches Drug Library Guide for Smart Infusion System

                                              Baxter International Inc. (BAX) recently introduced an infusion system drug library guide to help clinicians identify potential errors in the infusion process during intravenous treatment.

                                                Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown

                                                On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.

                                                  Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View

                                                  Quest Diagnostics' (DGX) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate.